Opinion

Video

Overview of the Port Delivery System with Ranibizumab

Margaret Chang, MD, examines the difficulties of frequent anti-VEGF injections and outlines the key aspects of the port delivery system (PDS) for ranibizumab administration.

  1. Why is sustained delivery of anti-VEGF necessary, and what challenges arise from frequent anti-VEGF injections?
  2. Can you provide an overview of the port delivery system with ranibizumab?
    1. How does the device function?
    2. How is the device implanted?
    3. How is the device refilled?
  3. What are the benefits of using the PDS with ranibizumab, and which patients are ideal candidates for this delivery method?
Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
AAO 2024: Enhancing the paradigm of 'see one, do one, teach one' with technology
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
© 2024 MJH Life Sciences

All rights reserved.